SERPINE1
|
0.600 |
GeneticVariation
|
group |
BEFREE |
The 4G/4G PAI-1 genotype was significantly associated with a high prevalence of arterial hypertension.
|
17351368 |
2007 |
SERPINE1
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Stroke prevalence and odds ratio (OR) were assessed for the following parameters: G20210A prothrombin, Arg506Glu factor V Leiden, C677T MTHFR, and 4G/5G PAI-1 polymorphisms; total number of study polymorphisms in a particular subject (genetic sum); and classic vascular risk factors of hypertension, obesity, diabetes mellitus, cigarette smoking, hypercholesterolemia, hypertriglyceridemia, and elevated levels of low-density lipoprotein (LDL) cholesterol and very low-density lipoprotein cholesterol.
|
24189452 |
2014 |
SERPINE1
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Influence of the 4G/5G PAI-1 genotype on angiotensin II-stimulated human endothelial cells and in patients with hypertension.
|
15194475 |
2004 |
SERPINE1
|
0.600 |
GeneticVariation
|
group |
BEFREE |
When stratified according to PAI-1 4G/5G polymorphism, there was no significant difference in all metabolic parameters among PAI-1 genotype groups in patients with HTN as well as subjects with normal blood pressure.
|
22613596 |
2012 |
SERPINE1
|
0.600 |
GeneticVariation
|
group |
BEFREE |
The most significant result among all univariate and multivariate tests performed in this study was the heterogeneity of correlation between PAI-1 and mean arterial pressure at rs10738554, near SLC24A2, a gene previously associated with high blood pressure in African Americans.
|
28408189 |
2017 |
SERPINE1
|
0.600 |
GeneticVariation
|
group |
BEFREE |
The functional plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism has previously been associated with hypertension.
|
21490692 |
2011 |
SERPINE1
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Hypertension (odds ratio [OR] = 1.953, p = 0.020), tHcy (OR = 1.059, p = 0.029), thyroid-stimulating hormone (OR = 0.876, p = 0.039), and the PAI-1 genotype dominant allele model (OR = 1.748, p = 0.047) were associated with IS by multivariate analysis.
|
30160528 |
2018 |
SERPINE1
|
0.600 |
GeneticVariation
|
group |
LHGDN |
The present study showed that the 4G/4G genotype was associated with elevated plasma PAI-1 activity in Chinese patients with and without hypertension.
|
12670745 |
2003 |
SERPINE1
|
0.600 |
GeneticVariation
|
group |
LHGDN |
The present study showed a positive association of the IL-6 GG genotype with hypertension and with elevated plasma PAI-1 level in normotensive individuals in a Chinese population in Taiwan.
|
15831362 |
2005 |
SERPINE1
|
0.600 |
GeneticVariation
|
group |
BEFREE |
The aims of this study were to observe associations of the genetic polymorphism for PAI-1 and t-PA with hypertension and atherothrombotic stroke, and to elucidate whether impaired fibrinolytic activity in atherothrombotic stroke was related to atherothrombosis per se or to other risk factors such as hypertension.
|
11385207 |
2001 |
SERPINE1
|
0.600 |
GeneticVariation
|
group |
BEFREE |
The T94G genotypes and plasma levels of adiponectin, and PAI-1 were determined in 568 Chinese patients, 212 with and 356 without hypertension, to study the possible associations of T94G genotype, plasma adiponectin, PAI-1 and blood pressure.
|
16741355 |
2007 |
SERPINE1
|
0.600 |
GeneticVariation
|
group |
BEFREE |
We found no associations between ACE I/D genotypes and plasma PAI-1 antigen concentrations in a subset of participants without major CHD risk factors (hypertension, hypercholesterolemia, overweight, smoking, diabetes) or in a small sample of African-Americans.
|
10997795 |
2000 |
SERPINE1
|
0.600 |
GeneticVariation
|
group |
BEFREE |
In conclusion, no association was found between M235T polymorphism and insulin resistance or PAI-1 levels, but results indicate relationship between I/D polymorphism of the ACE gene and plasma PAI-1 levels in the early stage of hypertension.
|
16981142 |
2006 |
SERPINE1
|
0.600 |
GeneticVariation
|
group |
BEFREE |
The present study showed a positive association of the IL-6 GG genotype with hypertension and with elevated plasma PAI-1 level in normotensive individuals in a Chinese population in Taiwan.
|
15831362 |
2005 |
SERPINE1
|
0.600 |
GeneticVariation
|
group |
LHGDN |
The 4G/4G PAI-1 genotype was significantly associated with a high prevalence of arterial hypertension.
|
17351368 |
2007 |
SERPINE1
|
0.600 |
Biomarker
|
group |
BEFREE |
Addition of waist circumference to the models either decreased or nullified the contribution of PAI-1act to BP and hypertension development.
|
31356402 |
2019 |
SERPINE1
|
0.600 |
Biomarker
|
group |
BEFREE |
These results demonstrates that hypertension and insulin resistance induced by COC is associated with increased cardiac RAS and PAI-1 gene expression, which is likely to be through corticosterone-dependent but not aldosterone-dependent mechanism.
|
26934364 |
2017 |
SERPINE1
|
0.600 |
Biomarker
|
group |
BEFREE |
Multivariate logistic regression analysis showed that PAI-1 4G/4G (P = 0.01) and the prevalence of hypertension (P < 0.0001) are independent risk factors of development of type 2 diabetic nephropathy.
|
10652041 |
2000 |
SERPINE1
|
0.600 |
Biomarker
|
group |
CTD_human |
Fosinopril and valsartan intervention in gene expression of Klotho, MMP-9, TIMP-1, and PAI-1 in the kidney of spontaneously hypertensive rats.
|
21051829 |
2010 |
SERPINE1
|
0.600 |
Biomarker
|
group |
BEFREE |
We observed significantly lower concentration of PAI-1:Ag in DF patients treated for hypertension as compared to patients without hypertension.
|
28193577 |
2017 |
SERPINE1
|
0.600 |
Biomarker
|
group |
BEFREE |
We compared concentrations of 4 different biomarkers (urinary albumin:creatinine ratio, circulating C-reactive protein, aldosterone:renin ratio, and plasminogen activator inhibitor-1) in nonhypertensive Framingham offspring study participants with none (n=233), 1 (n=474), or both (n=322) parents with hypertension.
|
18574071 |
2008 |
SERPINE1
|
0.600 |
Biomarker
|
group |
BEFREE |
Considering cardiovascular diseases there is a number of genes involved in lipid metabolism (apolipoproteins, lipoprotein receptors, lipolytic enzymes), thrombosis/hemostasis (platelet receptors, pro- and anticoagulant proteins, fibrinogen, PAI's), hypertension (angiotensin converting enzyme, angiotensinogen) glucose metabolism (glucose transporters, enzymes) and obesity (hormones, receptors), that are interesting candidates for sophisticated genetic risk assessment.
|
9654602 |
1998 |
SERPINE1
|
0.600 |
Biomarker
|
group |
CTD_human |
Vascular and thrombogenic effects of pulmonary exposure to Libby amphibole.
|
22352330 |
2012 |
SERPINE1
|
0.600 |
Biomarker
|
group |
BEFREE |
Post-phlebotomy, PRA and PAI-1 responses were more dramatic, but the NO response less in normotensive subjects having a parental history of hypertension, suggesting that these changes may represent familial, possibly genetic influences before overt hypertension occurs.
|
19154322 |
2008 |
SERPINE1
|
0.600 |
Biomarker
|
group |
BEFREE |
Although Angiotensin II-induced hypertension was blunted in PAI-1<sup>-/-</sup> mice, cardiac hypertrophy was accelerated.
|
28588076 |
2017 |